KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $370.0 million.

  • Bristol Myers Squibb's Capital Expenditures fell 211.64% to $370.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 504.81%. This contributed to the annual value of $1.3 billion for FY2025, which is 504.81% up from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Capital Expenditures is $370.0 million, which was down 211.64% from $320.0 million recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Capital Expenditures ranged from a high of $378.0 million in Q4 2024 and a low of $173.0 million during Q1 2021
  • Over the past 5 years, Bristol Myers Squibb's median Capital Expenditures value was $281.0 million (recorded in 2023), while the average stood at $293.0 million.
  • As far as peak fluctuations go, Bristol Myers Squibb's Capital Expenditures soared by 7647.06% in 2021, and later plummeted by 851.85% in 2022.
  • Over the past 5 years, Bristol Myers Squibb's Capital Expenditures (Quarter) stood at $320.0 million in 2021, then increased by 8.12% to $346.0 million in 2022, then dropped by 4.62% to $330.0 million in 2023, then grew by 14.55% to $378.0 million in 2024, then dropped by 2.12% to $370.0 million in 2025.
  • Its Capital Expenditures was $370.0 million in Q4 2025, compared to $320.0 million in Q3 2025 and $361.0 million in Q2 2025.